Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DPYD | Q12882 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104485 | 0.86 | KMT2A (0.51) | KMT2ATDP1MAPTLMNASMN1; SMN2 | |
| SCHEMBL13296 | 0.78 | DPYD (0.59) | KMT2ADPYDMAPTLMNASMN1; SMN2 | |
| SCHEMBL6510854 | 0.73 | DPYD (0.49) | DPYDMAPTLMNASMN1; SMN2 | |
| SCHEMBL153162 | 0.72 | KMT2A (0.73) | KMT2ATDP1MAPTSMN1; SMN2 | |
| SCHEMBL27482029 | 0.72 | KMT2A (0.49) | KMT2ATDP1 | |
| SCHEMBL6510851 | 0.72 | DPYD (0.47) | DPYDMAPTLMNASMN1; SMN2 | |
| SCHEMBL1525934 | 0.72 | KMT2A (0.73) | KMT2ATDP1MAPTLMNASMN1; SMN2 | |
| SCHEMBL27677766 | 0.72 | PDE3B (0.48) | TDP1MAPTLMNASMN1; SMN2 | |
| Thymine SCHEMBL14695416 | 0.71 | ATAD2 (0.66) | DPYDMAPTLMNASMN1; SMN2 | |
| SCHEMBL28628364 | 0.71 | LMNA (0.39) | KMT2ATDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321414-A1 | ENHANCEMENT OF SIRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND | Alnylam Pharmaceuticals Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010011895-A1 | ENHANCEMENT OF SIRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |